论文部分内容阅读
In one aspect of personalized medicine development,the patient population is thought of as a mixture of two subgroups that might derive differential efficacy,given treatment versus control.An important decision to make is whether to target the entire patient population(so-called all-comers),or just a subgroup of the patients.There are logical relationships among efficacy parameters in the subgroups and all-comers.